(Q31043603)

28 June 2017

1 reference

title

Present and potential future issues in glioblastoma treatment (English)

1 reference

28 June 2017

1 reference

Florence Lefranc

1

1 reference

28 June 2017

Niloufar Sadeghi

2

1 reference

28 June 2017

Isabelle Camby

3

1 reference

28 June 2017

Thierry Metens

4

1 reference

28 June 2017

Olivier Dewitte

5

1 reference

28 June 2017

Robert Kiss

6

1 reference

28 June 2017

1 May 2006

1 reference

Expert Review of Anticancer Therapy

28 June 2017

1 reference

28 June 2017

6

1 reference

28 June 2017

5

1 reference

28 June 2017

719-732

1 reference

Recommendations for the management of malignant gliomas in the elderly

28 June 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

The Treatment of Malignant Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Differential MRI diagnosis between brain abscesses and necrotic or cystic brain tumors using the apparent diffusion coefficient and normalized diffusion-weighted images

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Contribution of PET to the management of patients with low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Imaging gliomas with positron emission tomography and single-photon emission computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Surgical management of high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Patterns of care for adults with newly diagnosed malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Advances in neurosurgical technique in the current management of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Intraoperative magnetic resonance imaging combined with neuronavigation: a new concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Technology in the resection of gliomas and the definition of madness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Molecular mechanisms of glioma invasiveness: the role of proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Classification of glioblastoma multiforme in adults by molecular genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Genetic markers in glioblastoma: prognostic significance and future therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Characterization of astroglial versus oligodendroglial phenotypes in glioblastomas by means of quantitative morphonuclear variables generated by computer-assisted microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Glioblastomas with an oligodendroglial component: a pathological and molecular study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Role of radiation therapy and radiosurgery in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protoco

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Glioma classification: a molecular reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Pathways of apoptotic and non-apoptotic death in tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

"...those left behind." Biology and oncology of invasive glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Cost of Migration: Invasion of Malignant Gliomas and Implications for Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Mitogenic signaling cascades in glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Cancer: survival pathways meet their end.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Development of matrix metalloproteinase inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Current and Future Gene Therapy for Malignant Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

Intravenous, non-viral RNAi gene therapy of brain cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.5.719

21 January 2018

Identifiers

DOI

10.1586/14737140.6.5.719

1 reference

28 June 2017

1 reference